Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVR

Anteris Technologies Global Corp

Apr 30 • 03:38PM ET

6.05

+0.15 2.63 %

Healthcare • Medical Instruments & Supplies • USA • Small • NASD

Apr 28, 6:05 AMAnteris Technologies' PARADIGM trial for DurAVR valve gains U.S. Medicare reimbursement eligibility under CMS National Coverage Determination

Held by: IWM VXF IWO VTWO IWC VTWG RSSL FSYD VTHR ITWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.55	Insider Own	16.51%	Shs Outstand	97.23M	Perf Week	9.49%
Market Cap	588.74M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	45.24%	Shs Float	81.18M	Perf Month	9.10%
Enterprise Value	578.28M	PEG	-	EPS next Q	-0.16	Inst Own	35.58%	Short Float	5.09%	Perf Quarter	-3.12%
Income	-94.14M	P/S	308.24	EPS this Y	44.95%	Inst Trans	8.77%	Short Ratio	4.51	Perf Half Y	25.62%
Sales	1.91M	P/B	-	EPS next Y	23.38%	ROA	-179.15%	Short Interest	4.13M	Perf YTD	21.34%
Book/sh	-0.00	P/C	46.80	EPS next 5Y	31.02%	ROE	-300.45%	52W High	6.95 -12.87%	Perf Year	22.32%
Cash/sh	0.13	P/FCF	-	EPS past 3/5Y	-44.21% -	ROIC	-5858.37%	52W Low	2.85 112.46%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.77% -	Gross Margin	1.25%	Volatility	6.10% 6.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	302.76	EPS Y/Y TTM	-20.16%	Oper. Margin	-4908.21%	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.63	Sales Y/Y TTM	-29.23%	Profit Margin	-4921.28%	RSI (14)	56.97	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	0.67	EPS Q/Q	-38.92%	SMA20	5.18%	Beta	1.24	Target Price	14.42
Payout	-	Debt/Eq	-	Sales Q/Q	-42.18%	SMA50	2.86%	Rel Volume	0.47	Prev Close	5.90
Employees	174	LT Debt/Eq	-	Earnings	Feb 26 AMC	SMA200	23.42%	Avg Volume	915.57K	Price	6.05
IPO	Dec 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-47.03% 51.50%	Trades		Volume	403,773	Change	2.63%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	Cantor Fitzgerald	Overweight	$15
Mar-11-26	Initiated	Wells Fargo	Overweight	$16
Jan-08-25	Initiated	Lake Street	Buy	$20
Jan-07-25	Initiated	TD Cowen	Buy	$15
Jan-07-25	Initiated	Cantor Fitzgerald	Overweight	$9
Jan-07-25	Initiated	Barclays	Overweight	$22

Apr-28-26 06:00AM	Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial (GlobeNewswire)
02:53AM	Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances (Proactive)
Apr-01-26 11:47PM	A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market (Proactive)
Mar-05-26 05:03AM	Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference (MarketBeat)
Feb-26-26 06:41PM	Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway (Proactive)
06:00PM	Loading…
06:00PM	Anteris Reports 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-26 06:30AM	Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays (GlobeNewswire) +8.45%
Jan-24-26 09:01AM	Anteris Technologies price target lowered to $15 from $20 at Lake Street (TipRanks)
Jan-22-26 04:02PM	Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises (GlobeNewswire) +8.42%
04:01PM	Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock (GlobeNewswire)
11:28AM	Anteris Technologies announces $200M public offering to fund clinical growth (Proactive)
Jan-21-26 05:50AM	Medtronic to buy up to $90M stake in heart valve developer Anteris (MedTech Dive) +5.39%
01:38AM	What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours? (Benzinga)
Jan-20-26 10:53PM	Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering (GlobeNewswire) +12.52%
04:01PM	Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic (GlobeNewswire)
06:00AM	Loading…
Nov-17-25 06:00AM	Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves (GlobeNewswire)
Nov-12-25 05:52PM	Anteris Announces Results for the Third Quarter of 2025 (GlobeNewswire)
Nov-03-25 07:00AM	FDA Approves Anteris's DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
Oct-28-25 06:08PM	Anteris DurAVR THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year (GlobeNewswire) -7.84% -8.71%
Oct-27-25 05:43PM	Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
08:43AM	Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR THV to be Presented at TCT 2025 (GlobeNewswire)
Oct-15-25 09:18AM	Anteris Receives First European Regulatory Clearance to Commence DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
Sep-19-25 02:30AM	Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders (GlobeNewswire)
Sep-11-25 08:50AM	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders (GlobeNewswire)
Sep-04-25 01:42AM	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders (GlobeNewswire)
Aug-11-25 04:52PM	Anteris Announces Results for the Second Quarter of 2025 (GlobeNewswire) +6.00%
Jul-29-25 10:23AM	Anteris (AVR) Welcomes Two Directors as Major Trial Approaches (Insider Monkey)
Jun-09-25 10:52PM	Anteris Appoints David Roberts and Gregory Moss to its Board of Directors (GlobeNewswire) +13.29%
May-13-25 05:45PM	Anteris Announces Results for the First Quarter of 2025 (GlobeNewswire) -9.89%
Mar-31-25 07:15AM	Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV (GlobeNewswire)
07:30AM	Loading…
Mar-21-25 07:30AM	Anteris Reports One-Year Patient Outcomes for DurAVR THV (GlobeNewswire) -10.16%
Mar-12-25 08:33PM	Anteris Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.18%
Feb-28-25 08:00AM	Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays (GlobeNewswire)
Dec-16-24 07:49PM	Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering (Business Wire)
Dec-12-24 10:34PM	Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering (Business Wire)

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
L1 Capital Pty Ltd	10% Owner	Jan 22 '26	Buy	5.75	5,000,000	28,750,000	13,219,814	Feb 09 08:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVR

Anteris Technologies Global Corp

Upgrade your Finviz experience